High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: Dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1133-1139

  Pasini, Felice ^a   de Manzoni, G ^b   Pedrazzani, C ^b   Grandinetti, A ^b   Durante, E ^a   Gabbani, M ^b   Tomezzoli, A ^b   Griso, C ^a   Guglielmi, A ^b   Pelosi, G ^c   Maluta, S ^b   Cetto, G L ^a   Cordiano, C ^b  

^a Azienda Ospedaliera   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chemoradiotherapy; Docetaxel; Esophageal cancer; Weekly chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; SKIN DISEASE; TREATMENT PLANNING; VOMITING; ADJUVANT CHEMOTHERAPY; ESOPHAGUS TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 24644441426     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi207     Document Type: Article

References (30)

1. Law S, Kwong DL, Kwok KF et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: Impact of chemoradiation and change in treatment strategy. Ann Surg 2003; 238: 339-347.
2. de Manzoni G, Pedrazzani C, Verlato G et al. Comparison of old and new TNM classification systems for nodal staging of adenocarcinoma of the gastro-oesophageal junction. Br J Surg 2004; 91: 296-303.
3. Wayman J, Bennett MK, Raimes SA et al. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002; 86: 1223-1229.
4. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230: 392-400.
5. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88: 338-356.
6. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
7. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagous. N Engl J Med 1997; 337: 161-167.
8. Burmeister BH, Smithers BM, Fitzgerald L et al. A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus. Proc Am Soc Clin Oncol 2002; 21: 518.
9. Urba SG, Orringer MB, Turrisi A et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313.
10. Le Prise E, Etienne PL, Meunier B et al. A randomized study of chemotherapy, radiation therapy and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73: 1779-1784.
11. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994; 41: 391-393.
12. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
13. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and metaanalysis. Gut 2004; 53: 925-930.
14. Al Sarraf M, Martz K, Herskovic A. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 1997; 15: 277-284.
15. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
16. Cooper JS, Guo DM, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal caner. Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999; 281: 1623-1627.
17. Bissery MC, Nohynek G, Sandeink GJ, Lavelle F. Docetaxel (Taxotere® : A review of preclinical and clinical experience. Part I: Preclinical experience. Anti Cancer Drugs 1995; 6: 339-368.
18. Mason KA, Hunter NR, Milas M, Abruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997; 3: 2431-2438.
19. Amorino GP, Hamilton VM, Choy H. Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. Radiat Oncol Invest 1999; 7: 343-352.
20. Smorenburg CH, Sparreboom A, Verweij J. Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Review. Eur J Cancer 2001; 37: 2310-2323.
21. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric-junction. Br J Surg 1998; 85: 1457-1459.
22. de Manzoni G, Pedrazzani C, Pasini F et al. Results of surgical treatment of adenocarcinoma of the gastric cardia. Ann Thorac Surg 2002; 73: 1035-1040.
23. Japanese Gastric Cancer Association (JGCA). Japanese Gastric Cancer Association (JGCA) The new Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer 1998; 1: 1-15.
24. Sobin LH, Wittekind C (eds): International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 5th edition. New York: John Wiley 1997.
25. Brenner B, Ilson DH, Minsky BD et al. Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004; 22: 45-52.
26. Roth AD, Maibach R, Martinelli G et al. Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Ann Oncol 2000; 11: 301-306.
27. Haller DG, Misset JL. Docetaxel in advanced gastric cancer. Anticancer Drugs 2002; 13: 451-460.
28. Ajani JA, Van Cutcem E, Moiseyenko V. Docetaxel (D), cisplatin, 5-fluoruracil compared to cisplatin and 5-fluoruracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin. Oncol 2003; 22: 249 (Abstr 999).
29. Mudad R, Ramsey M, Kovitz K et al. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study. Lung Cancer 2003; 39: 173-177.
30. Wu HG, Bang YJ, Choi EK et al. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 75-80.